NCT00137839View on ClinicalTrials.gov

Erlotinib in Women With Previously Untreated Adenocarcinoma of the Lung

PHASE2CompletedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

November 30, 2004

Primary Completion Date

November 30, 2008

Study Completion Date

July 31, 2019

Conditions
AdenocarcinomaNon-small Cell Lung Cancer
Interventions
DRUG

Erlotinib

Trial Locations (3)

02114

Massachusetts General Hospital, Boston

02115

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Dana-Farber Cancer Institute

OTHER

collaborator

Massachusetts General Hospital

OTHER

collaborator

Brigham and Women's Hospital

OTHER

collaborator

Beth Israel Deaconess Medical Center

OTHER

collaborator

Genentech, Inc.

INDUSTRY

lead

Pasi A. Janne, MD, PhD

OTHER